Pharmacologic management of non-neurogenic functional obstruction in women

References

• Haylen BT, De Ridder D, Freeman RM, et al. An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20.
   PubMed Web of Science ®Google Scholar
• Osman NI, Chapple CR, Abrams P, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol. 2014;65:389–398.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Chancellor MB. Differential diagnosis and treatment of impaired bladder emptying. Rev Urol. 2004;6:S24–S31.
   PubMedGoogle Scholar
• King AB, Goldman HB. Bladder outlet obstruction in women: functional causes. Curr Urol Rep. 2014;15:436.
   PubMedGoogle Scholar
• Yoshimura N, Chancellor MB. Physiology and pharmacology of the bladder and urethra. In: Wein AJ, Kavoussi LR, Novick AC, et al., editors. Campbell-walsh urology. Philadelphia (PA): Saunders; 2012. p. 1786–1833.
   Google Scholar
• Gacci M, Andersson K-E, Chapple C, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016. doi:10.1016/j.eururo.2015.12.048.
   PubMed Web of Science ®Google Scholar
• Gupta P, Ehlert MJ, Sirls LT, et al. Percutaneous tibial nerve stimulation and sacral neuromodulation: an update. Curr Urol Rep. 2015;16:4.
   PubMed Web of Science ®Google Scholar
• Bosch JLHR. An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010? BJU Int. 2010;106:1432–1442.
   PubMed Web of Science ®Google Scholar
• Artibani W, Cerruto MA. Dysfunctional voiding. Curr Opin Urol. 2014;24:330–335.
   PubMed Web of Science ®Google Scholar
• Groutz A, Blaivas JG, Pies C, et al. Learned voiding dysfunction (non-neurogenic, neurogenic bladder) among adults. Neurourol Urodyn. 2001;20:259–268.
   PubMed Web of Science ®Google Scholar
• Osman NI, Chapple CR. Fowler’s syndrome–a cause of unexplained urinary retention in young women? Nat Rev Urol. 2014;11:87–98.
   PubMed Web of Science ®Google Scholar
• Minardi D, d’Anzeo G, Parri G, et al. The role of uroflowmetry biofeedback and biofeedback training of the pelvic floor muscles in the treatment of recurrent urinary tract infections in women with dysfunctional voiding: a randomized controlled prospective study. Urology. 2010;75:1299–1304.
   PubMed Web of Science ®Google Scholar
• Carlson KV, Rome S, Nitti VW. Dysfunctional voiding in women. J Urol. 2001;165:143–147; discussion 147–148.
   PubMed Web of Science ®Google Scholar
• Prescribing Information: Valium. [ updated 2008]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/013263s083lbl.pdf
   Google Scholar
• Riss J, Cloyd J, Gates J, et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008;118:69–86.
   PubMed Web of Science ®Google Scholar
• Blok BF, Holstege G. The central control of micturition and continence: implications for urology. BJU Int. 1999;83(Suppl 2):1–6.
   PubMed Web of Science ®Google Scholar
• Ong J, Kerr DI. GABA-receptors in peripheral tissues. Life Sci. 1990;46:1489–1501.
   PubMed Web of Science ®Google Scholar
• László Á, Nádasy GL, Monos E, et al. The GABAergic system in human female genital organs [Internet]. In: Erdö SL, editor. GABA Outside the CNS. Berlin: Springer; 1992. p. 183–197.
   Google Scholar
• Davidoff RA. Antispasticity drugs: mechanisms of action. Ann Neurol. 1985;17:107–116.
   PubMed Web of Science ®Google Scholar
• Mathew A, Mathew MC, Thomas M, et al. The efficacy of diazepam in enhancing motor function in children with spastic cerebral palsy. J Trop Pediatr. 2005;51:109–113.
   PubMed Web of Science ®Google Scholar
• Heymen S, Scarlett Y, Jones K, et al. Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation. Dis Colon Rectum. 2007;50:428–441.
   PubMed Web of Science ®Google Scholar
• Crisp CC, Vaccaro CM, Estanol MV, et al. Intra-vaginal diazepam for high-tone pelvic floor dysfunction: a randomized placebo-controlled trial. Int Urogynecol J. 2013;24:1915–1923.
   PubMed Web of Science ®Google Scholar
• Prescribing Information: Diastat. [updated 2014 Dec]. Available from: http://www.diastat.com/Portals/_default/Skins/diastat/Diastat-Administration-Instructions.pdf
   Google Scholar
• Katz DF, Yuan A, Gao Y. Vaginal drug distribution modeling. Adv Drug Deliv Rev. 2015;92:2–13.
   PubMed Web of Science ®Google Scholar
• Capra P, Perugini P, Bleve M, et al. Innovative approach for interstitial cystitis: vaginal pessaries loaded diazepam—A preliminary study, innovative approach for interstitial cystitis: vaginal pessaries loaded diazepam—a preliminary study. J Pharm J Pharm. 2013;2013:e386546.
   Google Scholar
• Rogalski MJ, Kellogg-Spadt S, Hoffmann AR, et al. Retrospective chart review of vaginal diazepam suppository use in high-tone pelvic floor dysfunction. Int Urogynecol J. 2010;21:895–899.
   PubMed Web of Science ®Google Scholar
• Prescribing Information: Lioresal. [updated 2013 Jan]. Available from: http://www.novartis.com.au/PI_PDF/lrst.pdf
   Google Scholar
• Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicuculline-insensitive GABA B sites in rat brain. Nature. 1981;290:149–152.
   PubMed Web of Science ®Google Scholar
• Clearfield JS, Nelson MES, McGuire J, et al. Intrathecal baclofen dosing regimens: a retrospective chart review. Neuromodulation J Int Neuromodulation Soc. 2015. doi:10.1111/ner.12361.
   Google Scholar
• Borrini L, Bensmail D, Thiebaut J-B, et al. Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults. Arch Phys Med Rehabil. 2014;95:1032–1038.
   PubMed Web of Science ®Google Scholar
• Xu D, Qu C, Meng H, et al. Dysfunctional voiding confirmed by transdermal perineal electromyography, and its effective treatment with baclofen in women with lower urinary tract symptoms: a randomized double-blind placebo-controlled crossover trial. BJU Int. 2007;100:588–592.
   PubMed Web of Science ®Google Scholar
• Stetkarova I, Brabec K, Vasko P, et al. Intrathecal baclofen in spinal spasticity: frequency and severity of withdrawal syndrome. Pain Physician. 2015;18:E633–E641.
   PubMed Web of Science ®Google Scholar
• Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139:919–922.
   PubMed Web of Science ®Google Scholar
• Prescribing information: Botox. [revised 2016 Jan]. Available from: http://www.allergan.com/assets/pdf/botox_pi.pdf
   Google Scholar
• Apostolidis A, Dasgupta P, Denys P, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a european consensus report. Eur Urol. 2009;55:100–120.
   PubMed Web of Science ®Google Scholar
• Kiris E, Burnett JC, Kane CD, et al. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem. 2014;14:2044–2061.
   PubMed Web of Science ®Google Scholar
• Barr JR, Moura H, Boyer AE, et al. Botulinum neurotoxin detection and differentiation by mass spectrometry. Emerg Infect Dis. 2005;11:1578–1583.
   PubMed Web of Science ®Google Scholar
• Phelan MW, Franks M, Somogyi GT, et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001;165:1107–1110.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Betts CD, Christmas TJ, et al. Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol. 1992;70:387–389.
   PubMedGoogle Scholar
• Kuo H-C. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003;170:1908–1912.
   PubMed Web of Science ®Google Scholar
• Kuo H-C. Effectiveness of urethral injection of botulinum A toxin in the treatment of voiding dysfunction after radical hysterectomy. Urol Int. 2005;75:247–251.
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Christmas TJ, Chapple CR, et al. Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: a new syndrome? BMJ. 1988;297:1436–1438.
   PubMed Web of Science ®Google Scholar
• Smith CP, Nishiguchi J, O’Leary M, et al. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65:37–41.
   PubMed Web of Science ®Google Scholar
• Crowner BE, Torres-Russotto D, Carter AR, et al. Systemic weakness after therapeutic injections of botulinum toxin A: a case series and review of the literature. Clin Neuropharmacol. 2010;33:243–247.
   PubMed Web of Science ®Google Scholar
• Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40:599–600.
   PubMed Web of Science ®Google Scholar
• Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004;171:2128–2137.
   PubMed Web of Science ®Google Scholar
• Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs Clin Immunother Biopharm Gene Ther. 2012;26:e1–e9.
   Google Scholar
• Schulte-Baukloh H, Weiss C, Stolze T, et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol. 2005;48:984–990; discussion 990.
   PubMed Web of Science ®Google Scholar
• Kuo H-C. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003;61:550–554.
   PubMed Web of Science ®Google Scholar
• Langford CF, Udvari Nagy S, Ghoniem GM. Levator ani trigger point injections: an underutilized treatment for chronic pelvic pain. Neurourol Urodyn. 2007;26:59–62.
   PubMed Web of Science ®Google Scholar
• Kuo TLC, Ng LG, Chapple CR. Pelvic floor spasm as a cause of voiding dysfunction. Curr Opin Urol. 2015;25:311–316.
   PubMed Web of Science ®Google Scholar
• Diokno AC, Hollander JB, Bennett CJ. Bladder neck obstruction in women: a real entity. J Urol. 1984;132:294–298.
   PubMed Web of Science ®Google Scholar
• Yalla SV, Resnick NM. Initiation of voiding in humans: the nature and temporal relationship of urethral sphincter responses. J Urol. 1997;157:590–595.
   PubMed Web of Science ®Google Scholar
• Crowe R, Noble J, Robson T, et al. An increase of neuropeptide Y but not nitric oxide synthase-immunoreactive nerves in the bladder neck from male patients with bladder neck dyssynergia. J Urol. 1995;154:1231–1236.
   PubMed Web of Science ®Google Scholar
• Kuo H-C. Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology. 2005;66:1005–1009.
   PubMed Web of Science ®Google Scholar
• Brucker BM, Fong E, Shah S, et al. Urodynamic differences between dysfunctional voiding and primary bladder neck obstruction in women. Urology. 2012;80:55–60.
   PubMed Web of Science ®Google Scholar
• Kumar A, Mandhani A, Gogoi S, et al. Management of functional bladder neck obstruction in women: use of alpha-blockers and pediatric resectoscope for bladder neck incision. J Urol. 1999;162:2061–2065.
   PubMed Web of Science ®Google Scholar
• Blaivas JG, Flisser AJ, Tash JA. Treatment of primary bladder neck obstruction in women with transurethral resection of the bladder neck. J Urol. 2004;171:1172–1175.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wu Z-J, Xu L, et al. Bladder neck incision for female bladder neck obstruction: long-term outcomes. Urology. 2014;83:762–766.
   PubMed Web of Science ®Google Scholar
• Markić D, Maričić A, Oguić R, et al. Transurethral bladder neck incision in women with primary bladder neck obstruction. Wien Klin Wochenschr. 2014;126:217–222.
   PubMed Web of Science ®Google Scholar
• Peng C-H, Kuo H-C. Transurethral incision of bladder neck in treatment of bladder neck obstruction in women. Urology. 2005;65:275–278.
   PubMed Web of Science ®Google Scholar
• Jin X, Qu H, Liu H, et al. Modified transurethral incision for primary bladder neck obstruction in women: a method to improve voiding function without urinary incontinence. Urology. 2012;79:310–313.
   PubMed Web of Science ®Google Scholar
• Nasu K, Moriyama N, Fukasawa R, et al. Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol. 1998;123:1289–1293.
   PubMed Web of Science ®Google Scholar
• Taki N, Taniguchi T, Okada K, et al. Evidence for predominant mediation of alpha1-adrenoceptor in the tonus of entire urethra of women. J Urol. 1999;162:1829–1832.
   PubMed Web of Science ®Google Scholar
• Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015;22(Suppl 1):7–17.
   PubMedGoogle Scholar
• Prescribing information: Flomax. [revised 2016 Jan]. Available from: http://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Flomax%20Caps/Flomax.pdf
   Google Scholar
• Guthrie RM, Siegel RL. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). Clin Ther. 1999;21:1732–1748.
   PubMed Web of Science ®Google Scholar
• Martell N, Luque M, HT-BPH Group. Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy. J Clin Hypertens Greenwich Conn. 2001;3:218–223.
   PubMedGoogle Scholar
• Prescribing information: Hytrin. [revised 2009 Jul]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019057s022lbl.pdf
   Google Scholar
• Lepor H, Knapp-Maloney G, Sunshine H. A dose titration study evaluating terazosin, a selective, once-a-day alpha 1-blocker for the treatment of symptomatic benign prostatic hyperplasia. J Urol. 1990;144:1393–1397; discussion 1397–1398.
   PubMed Web of Science ®Google Scholar
• Lepor H, Henry D, Laddu AR. The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate. 1991;18:345–355.
   PubMed Web of Science ®Google Scholar
• Kessler TM, Studer UE, Burkhard FC. The effect of terazosin on functional bladder outlet obstruction in women: a pilot study. J Urol. 2006;176:1487–1492.
   PubMed Web of Science ®Google Scholar
• Low BY, Liong ML, Yuen KH, et al. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol. 2008;179:1461–1469.
   PubMed Web of Science ®Google Scholar
• Page No:8 Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170:498–502.
   PubMed Web of Science ®Google Scholar
• Reitz A, Haferkamp A, Kyburz T, et al. The effect of tamsulosin on the resting tone and the contractile behaviour of the female urethra: a functional urodynamic study in healthy women. Eur Urol. 2004;46:235–240.
   PubMed Web of Science ®Google Scholar
• Pischedda A, Pirozzi Farina F, Madonia M, et al. Use of alpha1-blockers in female functional bladder neck obstruction. Urol Int. 2005;74:256–261.
   PubMed Web of Science ®Google Scholar
• Chang S-J, Chiang I-N, Yu H-J. The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol Off J Jpn Urol Assoc. 2008;15:981–985.
   Web of Science ®Google Scholar
• Lee K-S, Han DH, Lee Y-S, et al. Efficacy and safety of tamsulosin for the treatment of non-neurogenic voiding dysfunction in females: a 8-week prospective study. J Korean Med Sci. 2010;25:117–122.
   PubMed Web of Science ®Google Scholar
• Kim S-O, Hwang EC, Oh KJ, et al. Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml/s. Int Urogynecol J. 2011;22:1287–1291.
   PubMed Web of Science ®Google Scholar
• Pummangura N, Kochakarn W. Efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in women. Asian J Surg Asian Surg Assoc. 2007;30:131–137.
   PubMed Web of Science ®Google Scholar
• Costantini E, Lazzeri M, Bini V, et al. Open-label, longitudinal study of tamsulosin for functional bladder outlet obstruction in women. Urol Int. 2009;83:311–315.
   PubMed Web of Science ®Google Scholar
• Hajebrahimi S, Asrbadr YA, Azaripour A, et al. Effect of tamsulosin versus prazosin on clinical and urodynamic parameters in women with voiding difficulty: a randomized clinical trial. Int J Gen Med. 2011;4:35–39.
   PubMedGoogle Scholar
• Kim S-O, Choi HS, Kwon D. The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women. Urol J. 2014;11:1636–1641.
   PubMed Web of Science ®Google Scholar
• Swinn MJ, Kitchen ND, Goodwin RJ, et al. Sacral neuromodulation for women with Fowler’s syndrome. Eur Urol. 2000;38:439–443.
   PubMed Web of Science ®Google Scholar
• Goh M, Diokno AC. Sacral neuromodulation for nonobstructive urinary retention–is success predictable? J Urol. 2007;178:197–199; discussion 199.
   PubMed Web of Science ®Google Scholar
• DasGupta R, Fowler CJ. Urodynamic study of women in urinary retention treated with sacral neuromodulation. J Urol. 2004;171:1161–1164.
   PubMed Web of Science ®Google Scholar